UNSPSC 51181627: Liothyronine sodium

This classification denotes a generic primary tumor tnm finding with the molecular formula C15H11I3NO4.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GCA9VV7D2N, chemically known as l-tyrosine, o-(4-hydroxy-3-iodophenyl)-3,5-diiodo-, monosodium salt, but more generally known as liothyronine sodium, which bears US NIH Compound Identifier 5919. European Medicines Agency schedules liothyronine sodium or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08527MIG.

Most nations, for tariff purposes, schedule liothyronine sodium under HS 29374000. Liothyronine sodium bears US NLM identifiers UMLS ID C0546882 and NCI Concept Code C2581. SMILES: C1CC(C(CC1OC2C(CC(CC2I)C[C@@H](C(=O)[O-])N)I)I)O.[NA+].

UNSPSC 51181627 Liothyronine sodium is a Commodity code covering the procurement of this synthetic thyroid hormone medication by state and local health systems, correctional facilities, and public health agencies. State and local governments purchase liothyronine sodium primarily through formulary agreements with pharmaceutical wholesalers and direct vendor contracts to supply inpatient and outpatient clinical settings, correctional medical departments, and public health clinics. The drug treats hypothyroidism and is a standard item in hospital pharmacy inventory, acquired through routine pharmaceutical supply agreements rather than specialized or high-volume solicitations. Purchasing entities include state departments of health, state prison systems, county health departments, municipal hospitals, and hospital districts, which typically procure the medication as part of broader pharmaceutical supply contracts or through standing agreements with primary care and endocrinology service lines.

The source provides no recent state and local contract opportunities or solicitations under this code. Without posted RFPs, RFQs, IFBs, or ITBs naming this commodity, geographic concentration and specific issuing-body activity cannot be characterized from current market signals.